HALOZYME THERAPEUTICS, INC. — Form 8-K
Filed September 18, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 68/100
What the filing says
Halozyme priced $1.3B aggregate principal of 1.50% convertible senior notes due 2033 (upsized from $1.05B announced), with a 13-day overallotment option for up to $200M additional. Conversion price is $139.84/share (27.5% premium to $109.68 closing price on 9/17/26). Net proceeds ~$1.275B ($1.471B if overallotment exercised) will be used to fund $162.5M capped call transactions, repurchase $651.7M principal of existing 2027/2028 convertible notes (~$652.5M total cost), and general corporate purposes including potential acquisitions.
Why this rating
Large financing (~29% of $4.5B market cap) materially extends debt maturity profile and repays near-term convertibles, but modest 1.50% coupon and equity upside structure are positive. Neutral impact—financial engineering transaction, not operational.
See more from September 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.